Shipping to United States We Offer Worldwide Shipping
Login Wishlist

1-Hydroxy-2-methylanthraquinone

$672

  • Brand : BIOFRON

  • Catalogue Number : BD-P0356

  • Specification : 95.0%(HPLC)

  • CAS number : 6268-09-3

  • Formula : C15H10O3 

  • Molecular Weight : 238.2

  • PUBCHEM ID : 160817

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0356

Analysis Method

HPLC,NMR,MS

Specification

95.0%(HPLC)

Storage

2-8°C

Molecular Weight

238.2

Appearance

Yellow cryst.

Botanical Source

Structure Type

Anthraquinones

Category

Standards;Natural Pytochemical;API

SMILES

CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)O

Synonyms

1-Hydroxy-2-methyl-9,10-anthraquinone/1-Hydroxy-2-methyl-anthrachinon/1-Hydroxy-2-methyl-9,10-anthracenedione/1-hydroxy-2-methyl-anthraquinone/1-Hydroxy-2-methylanthraquinone

IUPAC Name

1-hydroxy-2-methylanthracene-9,10-dione

Applications

Density

1.371g/cm3

Solubility

Acetone

Flash Point

236.8ºC

Boiling Point

444.6ºC at 760 mmHg

Melting Point

184-185 ºC

InChl

InChl Key

CZODYZFOLUNSFR-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2914690000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:6268-09-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27992315

Abstract

Y220C, a substitution mutation in p53, causes major structural changes in the protein and is known to form a new protein cavity. This cavity is reckoned to accommodate small drug candidates that may play a key role in cancer treatment. Present study was aimed at determining a drug candidate that could inhibit the mutant p53 based on structural drug rationale. Docking of mutated p53 was performed to determine the drug of choice from the derivatives of 1-hydroxy-2- methylanthraquinone exhibiting anti-cancer properties. The cavity had been tested for identification of an accurate position vector for molecular docking studies using structure based drug design. The docked structure was validated using discovery studio 3.5. The best choice of two molecules were obtained by docking in specific solvent for 6 nanoseconds at a temperature of 310 K. Out of a library of compounds, acetamido-2-carboxy-4-dimethylamino-2- hydroxybenzophenone satisfied the ADMET and was found to be a potential target for mutant p53. This ligand binds at the active site of the protein. Results of present study offer a rationale of the lead ligands that can rescue oncogenic p53 by targeting the mutation site. Therefore, it is suggestive that small molecules may serve as an effective and novel anti-cancer drug.

Title

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.

Author

Ahire V1, Das D2, Mishra KP3, Kulkarni GR4, Ackland L5

Publish date

2016